Your browser is no longer supported. Please, upgrade your browser.
Settings
GNFT Genfit SA daily Stock Chart
GNFT [NASD]
Genfit SA
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand38.83M Perf Week-7.56%
Market Cap204.25M Forward P/E- EPS next Y- Insider Trans- Shs Float38.83M Perf Month-73.43%
Income- PEG- EPS next Q- Inst Own3.37% Short Float0.48% Perf Quarter-66.35%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio1.73 Perf Half Y-65.37%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-78.17%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range5.21 - 24.85 Perf YTD-73.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-78.83% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low0.96% ATR1.41
Employees194 Current Ratio- Sales Q/Q1354.40% Oper. Margin- RSI (14)20.23 Volatility5.49% 6.42%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.23 Prev Close5.22
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume106.91K Price5.26
Recom- SMA20-63.43% SMA50-65.77% SMA200-67.85% Volume131,111 Change0.77%
May-13-20Downgrade Kepler Buy → Reduce
May-12-20Downgrade H.C. Wainwright Buy → Neutral $46 → $11
May-12-20Downgrade Barclays Overweight → Equal Weight $55 → $14
Oct-29-19Reiterated B. Riley FBR Buy $52 → $43
Jun-25-19Initiated Stifel Hold
Apr-24-19Initiated SVB Leerink Outperform $58
Apr-22-19Initiated Barclays Overweight
May-26-20 01:19PM  Intercept Down on Postponement of AdCom Meet for NASH Drug Zacks
May-14-20 05:31PM  After Drug Failure, Genfit's Cupboard Is Nearly Bare GuruFocus.com -6.31%
May-12-20 02:20PM  Here's Why Shares of Durect Jumped Higher Today Motley Fool -67.73%
01:17PM  Why Genfit Is Cratering Today Motley Fool
11:03AM  GNFT Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SA and Encourages Investors to Contact the Firm ACCESSWIRE
08:06AM  The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings Benzinga
04:39AM  Genfit Craters 49% On Failed NASH Trial; Top Analyst Not Surprised SmarterAnalyst
04:35AM  Genfit Plunges After Liver Medicine Falls Short in Study Bloomberg
May-11-20 05:52PM  This Biotech Just Lost Half Its Value After A Key Hepatitis Drug Failed Investor's Business Daily
Apr-17-20 08:43AM  Why Genfit (GNFT) Stock Might be a Great Pick Zacks
Apr-11-20 02:32AM  Genfit SA (EPA:GNFT) Just Released Its Full-Year Earnings: Here's What Analysts Think Simply Wall St.
Mar-30-20 06:06PM  FDA Decisions on 5 Drugs Expected in 2nd Quarter GuruFocus.com
Mar-04-20 04:26PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFT GlobeNewswire
Mar-03-20 02:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFT ACCESSWIRE
Mar-02-20 05:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFT PR Newswire
10:25AM  GNFT ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SA And Encourages Investors to Contact the Firm ACCESSWIRE
Feb-26-20 03:06PM  GNFT ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SA PR Newswire
Feb-25-20 03:10PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFT ACCESSWIRE -7.24%
11:00AM  GNFT ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SA GlobeNewswire
Feb-24-20 04:45PM  GNFT ALERT - Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Genfit SA ACCESSWIRE -5.66%
02:23PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Genfit SA - GNFT GlobeNewswire
Feb-21-20 11:57AM  Genfit Delays Data From Liver-Disease Study. Analysts Are Confused and the Stock Is Falling. Barrons.com
Feb-17-20 05:35AM  Imagine Owning Genfit (EPA:GNFT) And Trying To Stomach The 76% Share Price Drop Simply Wall St.
Jan-08-20 07:37AM  Will Genfit Continue to Surge Higher? Zacks
Jan-02-20 09:08AM  Intercept Pharma Has a New Liver Drug. Dont Expect FDA Approval to Lift the Stock, Analyst Says. Barrons.com
Dec-22-19 05:32PM  Hedge Funds Arent Crazy About Genfit SA (GNFT) Anymore Insider Monkey
Dec-10-19 03:36PM  Genfit Hopes to Buck the Odds With NASH Drug GuruFocus.com
Nov-26-19 08:06AM  The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug Benzinga
Nov-18-19 02:57AM  Is Genfit SA (EPA:GNFT) A Volatile Stock? Simply Wall St.
Nov-09-19 02:58PM  Hedge Funds Are Dumping Genfit SA (GNFT) Insider Monkey
Oct-03-19 09:29AM  Is Genfit (EPA:GNFT) A Risky Investment? Simply Wall St.
Aug-19-19 02:45PM  Obesity Epidemic Leads To A New Problem And It Could Be Worth Billions Investor's Business Daily +6.65%
Aug-13-19 02:10AM  Did Changing Sentiment Drive Genfit's (EPA:GNFT) Share Price Down By 47%? Simply Wall St.
Jul-08-19 04:32AM  Could Genfit SA's (EPA:GNFT) Investor Composition Influence The Stock Price? Simply Wall St.
Jun-29-19 06:18PM  Hedge Funds Have Never Been This Bullish On Genfit SA (GNFT) Insider Monkey
Jun-25-19 07:15AM  The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership Benzinga
Jun-24-19 04:31PM  Terns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China Region Business Wire
Jun-17-19 01:50PM  ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention Benzinga
May-09-19 02:00PM  Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat Zacks
May-02-19 03:43PM  Genfit, Cymbay Hope to Crack Large Liver Disease Market GuruFocus.com
May-01-19 11:12AM  Zacks.com featured highlights include: Teledyne, Genfit, Shoe Carnival, ZTO and GCI Zacks
Apr-30-19 10:24AM  5 Stocks to Buy on New Analyst Coverage Zacks
Apr-25-19 10:11AM  Top Ranked Momentum Stocks to Buy for April 25th Zacks
Apr-24-19 09:04AM  Can This NASH Stock Really Double Your Money? Motley Fool
Apr-15-19 04:26PM  Gilead to Collaborate with Novo Nordisk for NASH Treatment Zacks
Apr-07-19 02:00PM  3 Top Small-Cap Biotech Stocks for Aggressive Investors Motley Fool
Apr-02-19 06:34PM  5 IPOs Doing Better Than Lyft in 2019 GuruFocus.com
Mar-27-19 06:13PM  Nasdaq Welcomes GENFIT S.A. (Nasdaq: GNFT) to The Nasdaq Stock Market GlobeNewswire
Mar-24-19 05:16PM  IPO Outlook For The Week: Biopharm, Gene Editor And Lyft Benzinga
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.